anifrolumab   Click here for help

GtoPdb Ligand ID: 8258

Synonyms: anifrolumab-fnia | MDX-1333 | MEDI-546 | Saphnelo®
Approved drug Immunopharmacology Ligand
anifrolumab is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Anifrolumab is a monoclonal antibody targeting IFNAR1 (the receptor for α, β and ω interferons), that was developed by the MedImmune subsidiary of AstraZeneca as a treatment for systemic lupus erythematosus (SLE).
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. [3]. Sequence BLAST using the heavy and light chain variable regions of anifrolumab provides 100% matches to sequences that are claimed in patent US7662381 [3]. The sequence matches identify anifrolumab as clone 11E2 in the patent.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Anifrolumab was progressed to clinical development for SLE and for scleroderma. First approval was granted by the FDA in August 2021, for the indication of moderate to severe systemic lupus erythematosus (SLE) in patients who are receiving standard therapy.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IFNα appears to enhance the maturation or activation of dendritic cells (DCs) [6-10], and increased expression of type I interferons has been described in several autoimmune diseases including SLE [1-2,5,11] and insulin-dependent diabetes mellitus (IDDM) [4]. Pharmaceutical intervention options to combat elevated IFNα levels include neutralising circulating IFNα (as achieved by sifalimumab) or blocking/competitively inhibiting IFNα binding to its cognate receptor. The latter is the mechanism by which anifrolumab acts.